Nicox S.A. (EPA:ALCOX)

Market Cap	24.60M
Revenue (ttm)	3.32M
Net Income (ttm)	-27.06M
Shares Out	80.93M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	4.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,724
Average Volume	153,218
Open	0.3020
Previous Close	0.3040
Day's Range	0.3020 - 0.3090
52-Week Range	0.2000 - 0.6500
Beta	0.13
RSI	39.86
Earnings Date	Jan 23, 2026

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2024, Nicox's revenue was 7.86 million, an increase of 13.84% compared to the previous year's 6.90 million. Losses were -22.39 million, 7.23% more than in 2023.